Introduction
============

Hearing loss is a common communication disorder, affecting 1--3 newborns out of every 1,000 live births globally ([@b1-mmr-22-01-0077]). Survey data from the World Health Organization (<http://www.who.int>) indicates that 32 million individuals out of 360 million with hearing loss are pediatric patients ([@b2-mmr-22-01-0077],[@b3-mmr-22-01-0077]). Hearing loss can be caused by gene alterations and environmental factors, including ototoxic drugs such as aminoglycoside antibiotics (AmAn) ([@b4-mmr-22-01-0077]). Genetic alterations in human mitochondrial DNA (mtDNA) are also associated with deafness ([@b5-mmr-22-01-0077]). Moreover, A1555G and C1494T mtDNA mutations have been implicated in both AmAn-induced and non-syndromic hearing loss in patients worldwide ([@b6-mmr-22-01-0077]--[@b8-mmr-22-01-0077]). mt-transfer RNA(tRNA)^Ser(UCN)^ gene pathogenic mutations are associated with hearing loss ([@b9-mmr-22-01-0077]) and include A7445G ([@b10-mmr-22-01-0077]), 7472insC ([@b11-mmr-22-01-0077]), T7510C ([@b12-mmr-22-01-0077]) and T7511C ([@b13-mmr-22-01-0077]). Furthermore, mt-tRNA mutations may have structural and functional implications, such as affecting the processing of RNA precursors, nucleotide modification and aminoacylation ([@b14-mmr-22-01-0077]). However, the molecular mechanism underlying mt-tRNA^Ser(UCN)^ mutations and deafness are not fully understood.

To investigate the association between mt-tRNA^Ser(UCN)^ mutations and non-syndromic hearing loss, and to facilitate early diagnosis and prevention of mitochondrial-associated deafness, the present study performed genetic analyses for deafness-associated mtDNA mutations. The clinical and molecular features of two Chinese families with hearing impairment were assessed. PCR and Sanger sequencing analyses results suggested the presence of cytochrome *c* oxidase 1 (CO1)/tRNA^Ser(UCN)^ G7444A and tRNA^Ser(UCN)^ C7492T mutations in these families. Mutations in gap junction β-2 (GJB2), solute Carrier Family 26 Member 4 (SLC26A4) and TRNA 5-methylaminomethyl-2-thiouridylate methyltransferase (TRMU) genes are the most prevalent deafness causing genetic modifications worldwide ([@b15-mmr-22-01-0077]--[@b17-mmr-22-01-0077]). To examine the potential role of GJB2, SLC26A4 and TRMU in deafness, mutational analyses of these genes were performed in the matrilineal relatives in the two Chinese families.

Materials and methods
=====================

### Subjects and clinical examinations

In the present genetic screening program for deafness-associated mt-tRNA^Ser(UCN)^ mutations, two Chinese families with hearing loss were recruited from The Union Hospital, Tongji Medical College, Huazhong University of Science and Technology between January 2018 and January 2019 ([Fig. 1](#f1-mmr-22-01-0077){ref-type="fig"}). There were 11 matrilineal relatives in Family 1 (5 males and 6 females), one of them (III-12) was the deaf patient. There were 8 matrilineal relatives in Family 2 (3 males and 5 females), one of them (II-9) was the deaf patient. Comprehensive medical histories and physical examination were assessed to identify any syndromic findings, history of AmAn use and genetic factors related to hearing impairment. An age-appropriate audiological examination was performed by an experienced audiologist, including pure-tone audiometry (PTA) and/or auditory brainstem response (ABR), immittance testing and distortion product otoacoustic emissions. PTA was calculated from the average of the audiometric thresholds at 500, 1,000, 2,000, 4,000 and 8,000 Hz. The severity of hearing impairment was classified into five grades: i) Normal, \<26 decibel (dB); ii) mild =26--40 dB; iii) moderate =41--70 dB; iv) severe =71--90 dB; and v) profound \>90 dB ([@b18-mmr-22-01-0077]). The study was approved by the Ethics Committee of Union Hospital, Tongji Medical College, Huazhong University of Science and Technology. Signed written informed consent was obtained from the participants or their guardians. Control subjects (n=455; men, 200; women, 255; age, 20--45 years) were enrolled in the present study. The healthy subjects had normal hearing and did not have any mitochondrial disorders such as vision loss, neurological disorders, cancer or cardiovascular diseases. Subjects who had a family history of mitochondrial diseases or ongoing infectious disease, neoplastic disease, major surgery, severe liver dysfunction and inflammatory disease were excluded. Written informed consent was also provided by the control subjects.

### Genetic screening for mtDNA mutations or variants

PCR and direct sequence analysis were performed to detect deafness related mtDNA mutations or variants. Blood samples (5 ml) from the family members (II-10, II-8 and II-5 in Family 1; I-2, II-6 and II-8 in Family 2; [Fig. 1](#f1-mmr-22-01-0077){ref-type="fig"}), as well as from 455 controls were collected. Genomic DNA was isolated from probands from the two families (III-12 and II-9) using the Puregene DNA Isolation kits (Gentra Systems, Inc.). DNA was preserved at 20°C. Amplification of complete mtDNA genes was performed as previously described ([@b19-mmr-22-01-0077]). A PCR mixture containing 200 µM dNTPs, 10X buffer, Taq DNA polymerase and 15 mmol/l Mg^2+^ (Takara Biotechnology Co., Ltd.) was used for PCR, the primers\' sequences are listed in [Table I](#tI-mmr-22-01-0077){ref-type="table"}. The following PCR thermocycling conditions were used: Initial denaturation at 95°C for 5 min; 30 cycles of 94°C for 10 sec, 60°C for 30 sec and 72°C for 1 min; and a final extension at 72°C for 5 min. Subsequently, the 24 PCR products were purified and analyzed using Sanger sequence technology as previously described ([@b20-mmr-22-01-0077]). The complete mtDNA genes of the matrilineal relatives from the two families (II-10, II-8 and II-5 in Family 1; I-2, II-6 and II-8 in Family 2) were also amplified by PCR and sequenced as above. Data were then compared with the revised Cambridge Reference sequences (rCRS) from GenBank database to detect mtDNA mutations (GenBank accession no. NC_001807) ([@b21-mmr-22-01-0077]).

### Conservation assessments

The sequence alignment was performed by using the ClustalW program version 2.0 ([http;//www.ebi.ac.uk/Tools/msa/clustalw2/](http;//www.ebi.ac.uk/Tools/msa/clustalw2/)) ([@b22-mmr-22-01-0077]). The conservation index (CI) of each mtDNA variants or mutations identified in these two families were analyzed as previously described ([@b23-mmr-22-01-0077]). The CI was determined as the percentage of the sequence, from a list of 16 different vertebrates that possessed the wild-type nucleotide at the same position ([@b24-mmr-22-01-0077]), these species included *Bos Taurus, Cebus albifrons, Gorilla gorilla, Homo sapiens, Hylobates lar, Lemur catta, Macaca mulatta, Macaca sylvanus, Mus musculus, Nycticebus coucang, Pan paniscus, Pan troglodytes, Pongo pygmaeus, Pongo abelii, Papio hamadryas* and *Tarsius bancanus*.

### Screening for the GJB2, SLC26A4 and TRMU mutations

Mutations in GJB2, SLC26A4 and TRMU are associated with hearing impairment ([@b15-mmr-22-01-0077]--[@b17-mmr-22-01-0077]). To assess whether these nuclear genes play important roles in the clinical manifestation of hearing loss, a mutational screening for GJB2, SLC26A4 and TRMU was performed in the probands from these families (III-12 and II-9; [Fig. 1](#f1-mmr-22-01-0077){ref-type="fig"}). The primers used were as described previously ([@b17-mmr-22-01-0077],[@b19-mmr-22-01-0077],[@b20-mmr-22-01-0077]). The primers for PCR amplification of GJB2 were: Forward, 5′-TATGACACTCCCCAGCACAG-3′ and reverse, 5′-GGGGCAATGCTTAAACTGGC-3′. The five primer sequences for SLC26A4 were: Forward, 5′-CGTGTAGCAGCAGGAAGTAT-3′ and reverse, 5′-TTAAATAAAAAAGACTGACT-3′; forward, 5′-TGGGGAAAAAGGATGGTGGT-3′ and reverse, 5′-CCAACCCCTTCTTTAGCTGA-3′; forward, 5′-GCAGGATAGCTCAAGGAATT-3′ and reverse, 5′-TCATCAGGGAAAGGAAATAA-3′; forward, 5′-TCTCCTTGATGTCTTGCTTA-3′ and reverse, 5′-CCCATGTATTTGCCCTGTTG-3′; and forward, 5′-CTGGGCAATAGAATGAGACT-3′ and reverse, 5′-ATCTGTAGAAAGGTTGAATA-3′. The primers for TRMU amplification were: Forward, 5′-ACAGCGCAGAAGAAGAGCAGT-3′ and reverse, 5′-ACAACGCCACGACGGACG-3′. The PCR products were analyzed by direct Sanger sequencing as mentioned in a previous study ([@b19-mmr-22-01-0077]). The data were compared with published National Center for Biotechnology Information database sequences (<https://www.ncbi.nlm.nih.gov/pubmed>; GJB2, NM_004004; SLC26A4, NM_000441.1; TRMU, AF448221).

### Assessment of pathogenicity

The updated pathogenicity scoring system ([@b25-mmr-22-01-0077]) was used to assess the pathogenic status of CO1/tRNA^Ser(UCN)^ G7444A and tRNA^Ser(UCN)^ C7492T mutations. Using this approach, a mutation was classified as a 'neutral polymorphism' with a score ≤6, as 'possibly pathogenic' with a score from 7--10 and 'definitely pathogenic' with a score ≥11. The status of G7444A and C7492T mutations were also searched on the MITOMAP database ([www.mitomap.org](www.mitomap.org)) to confirm their pathogenicity ([@b26-mmr-22-01-0077]).

Results
=======

### Clinical presentation of two families with hearing loss

The present study investigated deafness related mt-tRNA^Ser(UCN)^ polymorphisms in two Chinese families with hearing impairment ([Fig. 1](#f1-mmr-22-01-0077){ref-type="fig"}). In Family 1, the proband (III-12) was a 15-year-old female patient who began to suffer bilateral hearing impairment at the age of 10 years old. No family members in Family 1 had a history of using AmAn. Audiological evaluation indicated that the 15-year-old female had profound hearing loss (118 and 110 dB for right and left ears, respectively; [Fig. 2](#f2-mmr-22-01-0077){ref-type="fig"}; [Table II](#tII-mmr-22-01-0077){ref-type="table"}). Furthermore, clinical examination identified that no other matrilineal relatives in Family 1, including the mother of the patient (II-10), had hearing loss.

In Family 2, the proband (II-9) was a 38-year-old female who was treated at the Otology Clinic of Union Hospital, Tongji Medical College, Huazhong University of Science and Technology for deafness. A comprehensive history and physical examination indicated that the proband (II-9) suffered bilateral hearing impairment at the age of 20 years old. Furthermore, the proband had profound hearing loss (103 and 99 dB for right and left ears, respectively; [Table II](#tII-mmr-22-01-0077){ref-type="table"}). However, all matrilineal relatives in Family 2 had normal hearing and none had a history of AmAn use ([Fig. 1](#f1-mmr-22-01-0077){ref-type="fig"}).

### Mitochondrial genome analysis

To investigate the molecular basis of hearing loss, mutational screening of mtDNA genes was performed in these families. First, the present study amplified the complete mitochondrial genomes of the probands in the families (III-12 and II-9) and the corresponding matrilineal relatives (II-10, II-8 and II-5 in Family 1; I-2, II-6 and II-8 in Family 2; [Fig. 1](#f1-mmr-22-01-0077){ref-type="fig"}). The resultant 24 PCR products were sequenced as previously described ([@b20-mmr-22-01-0077]). By comparing the present results with previous data from the rCRS ([@b21-mmr-22-01-0077]), a number of genetic variants were identified, in addition to the CO1/tRNA^Ser(UCN)^ G7444A and tRNA^Ser(UCN)^ C7492T mutations ([Fig. 3](#f3-mmr-22-01-0077){ref-type="fig"}; [Table III](#tIII-mmr-22-01-0077){ref-type="table"}). Moreover, ten variants were identified in the D-loop region, four known variants in 12S rRNA, four known variants in 16S rRNA and one 9-bp deletion in the non-coding region located between the CO2 and tRNA^Lys^ genes ([@b21-mmr-22-01-0077]). In addition, 26 variants were found in protein coding genes. These included five missense mutations: A8701G (Thr→Ala), A8860G (Thr→Ala) in ATP synthase membrane subunit 6, A10398G (Thr→Ala) in NADH-ubiquinone oxidoreductase chain 3 (ND3), C14766T (Thr→Ile) and A15326G (Thr→Ala) in Cytochrome B. Only the CO1/tRNA^Ser(UCN)^ G7444A and tRNA^Ser(UCN)^ C7492T mutations are highly conserved in various species, including humans ([@b21-mmr-22-01-0077]), bovines ([@b27-mmr-22-01-0077]), mice ([@b28-mmr-22-01-0077]) and *Xenopus laevis* ([@b29-mmr-22-01-0077]). The present phylogenetic analysis results indicated that none of the other identified variants were conserved, suggesting that the G7444A and C7492T mutations may have functional significance in deafness phenotype expression ([Figs. 3](#f3-mmr-22-01-0077){ref-type="fig"} and [4](#f4-mmr-22-01-0077){ref-type="fig"}). In addition, G7444A and C7492T mutations were not detected in 455 control subjects. Moreover, these mt-tRNA^Ser(UCN)^ mutations were not found in the matrilineal relatives (II-10, II-8 and II-5 in Family 1; I-2, II-6 and II-8 in Family 2).

In fact, the C7492T mutation occurred at position 26 in the anticodon stem of tRNA^Ser(UCN)^, nucleotide at that position was very conserved from different species ([@b21-mmr-22-01-0077]), while the G7444A mutation was localized at the conjunction between CO1 and tRNA^Ser(UCN)^ ([@b21-mmr-22-01-0077]).

### Genotyping analysis of GJB2, SLC26A4 and TRMU genes

Previous studies showed that GJB2 ([@b15-mmr-22-01-0077]), SCL26A4 ([@b17-mmr-22-01-0077]) and TRMU ([@b16-mmr-22-01-0077]) gene mutations are important causes of hereditary hearing loss. To investigate whether these nuclear genes played active roles in the phenotypic expression of deafness, mutational screening was performed. The present results suggested that no functional variants were identified in these nuclear genes.

### G7444A and C7492T are 'possibly pathogenic' mutations associated with deafness

A pathogenicity scoring system ([@b25-mmr-22-01-0077]) was used to evaluate the status of CO1/tRNA^Ser(UCN)^ G7444A and tRNA^Ser(UCN)^ C7492T mutations ([Table IV](#tIV-mmr-22-01-0077){ref-type="table"}). It was found that the total scores of G7444A and C7492T mutations were each nine points, and that these variants were 'possibly pathogenic' changes associated with hearing impairment.

Discussion
==========

The present study investigated the molecular and genetic features of two Chinese family with deafness related mt-tRNA^Ser(UCN)^ gene mutations. The mt-tRNA^Ser(UCN)^ gene has been implicated as a key site for mutations and variants associated with hearing impairment ([@b30-mmr-22-01-0077]--[@b32-mmr-22-01-0077]). In a previous genetic screening program for mt-tRNA^Ser(UCN)^ variants in 2,651 patients with deafness, the incidence rate of T7511C, T7505C and A7445C mutations were all 0.04% ([@b9-mmr-22-01-0077]). It has been suggested that the primary defect in mt-tRNA^Ser(UCN)^ mutations is tRNA metabolism failure, which affects mitochondrial translation and respiratory chain function ([@b33-mmr-22-01-0077]).

Using PCR and direct sequencing analysis, the present results identified two potential pathogenic mutations in the two families with hearing loss; G7444A and C7492T. The CO1/tRNA^Ser(UCN)^ G7444A mutation is on the mtDNA heavy strand and causes a read-through of the AGA stop codon in the CO1 gene. The CO1/tRNA^Ser(UCN)^ G7444A mutation adds three amino acids, Lys-Gln-Lys, to the C-terminus of the polypeptide ([@b34-mmr-22-01-0077]). In addition, the G7444A mutation is adjacent to the 3′ terminal endonucleolytic processing site of the L-strand RNA precursor, spanning tRNA^Ser(UCN)^ and ND6 mRNA ([@b35-mmr-22-01-0077]). Moreover, the deafness-associated A7445G mutation causes a significant decrease in the steady-state level of tRNA^Ser(UCN)^ and ND6 mRNA ([@b35-mmr-22-01-0077],[@b36-mmr-22-01-0077]). Thus, the G7444A mutation, which is similar to the A7445G mutation, may also cause impaired tRNA^Ser(UCN)^ metabolism, which plays an important role in deafness ([@b37-mmr-22-01-0077]). Kokotas *et al* ([@b38-mmr-22-01-0077]) investigated a Greek family with hearing loss and identified the co-existence of the G7444A mutation and the GJB2 c.35delG mutation.

Furthermore, in the present study, the homoplasmic C7492T mutation was identified in Family 2. Structurally, this mutation is located at position 26 of the tRNA^Ser(UCN)^ gene anticodon stem ([@b39-mmr-22-01-0077]). The nucleotide at this position is highly conserved between species, indicating that it plays a critical role in tRNA stability and normal function. Moreover, the heteroplasmic T4295C mutation, located at the same position in the tRNA^Ile^ gene, is a pathogenic mutation causing chronic progressive external ophthalmoplegia ([@b40-mmr-22-01-0077]). In addition, the C7492T mutation disrupts conserved base-pairing (A26-U44) and may cause the tRNA metabolism failure. The C7492T mutation is also associated with polycystic ovary syndrome (PCOS) ([@b41-mmr-22-01-0077]) and hypertension ([@b42-mmr-22-01-0077]). Thus, the present study hypothesized that the C7492T mutation may lead to mitochondrial dysfunction and may be involved in the pathogenesis of hearing loss. However, sequence analysis results for the complete mtDNA genes from the matrilineal relatives (II-10, II-8 and II-5 in Family 1; I-2, II-6 and II-8 in Family 2) indicated that the G7444A and C7492T mutations were only presented in the probands (III-12 in Family 1; II-9 in Family 2), but were absent in matrilineal relatives. Therefore, the present results suggested that G7444A and C7492T may be *de novo* mutations.

In total \>130 genes have been associated with hearing loss ([@b43-mmr-22-01-0077]). GJB2 encodes a gap junction protein that is expressed in the cochlea and is thought to be important for recycling potassium ions that flow into sensory hair cells as part of the transduction current ([@b44-mmr-22-01-0077]). Mutations in the GJB2 gene are a major cause of non-syndromic hearing loss ([@b45-mmr-22-01-0077]). Among these mutations, c.235delC and c.167delT are the most frequent variants among Eastern Asian populations ([@b46-mmr-22-01-0077]). Furthermore, SLC26A4 mutations contribute to non-syndromic enlarged vestibular aqueduct (MIM 600791) and Pendred syndrome (MIM 274600) ([@b47-mmr-22-01-0077]). Moreover, c.919\>2A\>G is the most frequent SLC26A4 gene mutation associated with non-syndromic hearing loss ([@b48-mmr-22-01-0077]). The TRMU gene, which encodes the mitochondrial tRNA-specific 2-thiouridylase, is regarded as a nuclear modified gene for the phenotypic manifestation of deafness-associated 12S rRNA mutations ([@b16-mmr-22-01-0077]). In a previous study, the A10S mutation in TRMU exon 1 was found to modulate the clinical expression of deafness related A1555G mutation in an Arab-Israel family ([@b16-mmr-22-01-0077]). However, in the present study, the absence of GJB2, SLC26A4 and TRMU variants in the two families suggested that these genes may not play a role in the clinical expression of hearing impairments.

Mitochondrial haplogroups may influence the phenotypic expression of hearing loss associated with mtDNA pathogenic mutations ([@b49-mmr-22-01-0077]). Mitochondrial haplogroup B may increase the risk for hearing impairment among patients with the A1555G mutation ([@b50-mmr-22-01-0077]). In addition, mitochondrial haplogroup specific variants including G15927A of haplogroup B5b, T12338C of haplogroup F2, T5802C, T10454C, C12224T and G11696A of haplogroup D4, G5821A of haplogroup C, A14693G of haplogroups Y2 and F, and T15908C of haplogroup Y2 may enhance the penetrance of hearing loss carrying the 12S rRNA A1555G mutation ([@b51-mmr-22-01-0077]). Sequence characterization of mitochondrial genomes in the present study identified sets of genetic polymorphisms belonging to the D4 and G2b Eastern Asian haplogroups ([@b52-mmr-22-01-0077]). However, phylogenetic conservation analysis showed that, except for the G7444A and C7492T mutations, the variants were not conserved. Collectively, the present results suggested that the mitochondrial genetic background may not play a significant role in the expression of deafness-associated pathogenic mtDNA mutations. Moreover, the pathogenicity scoring system indicated that the total scores of G7444A and C7492T mutations were both nine points, and belonged to the 'possibly pathogenic' classification associated with deafness; however, scoring needs to be examined using cybrid cells carrying the G7444A or C7492T mutation in future studies. Furthermore, data from the MITOMAP suggested that the C7492T mutation was likely benign. However, MITOMAP reports the published data on human mtDNA mutations or variants and does not analyze functions ([@b53-mmr-22-01-0077]). The C7492T mutation had been reported to be associated with PCOS ([@b41-mmr-22-01-0077]) and hypertension ([@b42-mmr-22-01-0077]), thus C7492T is a disease-associated mutation. However, in the present study, the incomplete penetrance of hearing loss and mild mitochondrial dysfunction indicated that G7444A and C7492T mutations are insufficient to produce the observed clinical phenotypes. Therefore, environmental factors and epigenetic modification may contribute to the expression of the deafness phenotype.

There are several limitations in the present study. Functional analysis was not performed for the C7492T and G7444A mutations, and the small sample size is major limitation. Further studies, including more patients with deafness and using trans-mitochondrial cybrid cells are required to investigate the present results in more depth.
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###### 

Primer sequence information for amplification of complete mitochondrial genome.

  Primer name   Direction   Primer Sequence (5′-3′)   Target region (bp)   Tm (°C)
  ------------- ----------- ------------------------- -------------------- ---------
  Mit-1         F           CTCCTCAAAGCAATACACTG      592-1430             59.7
                R           TGCTAAATCCACCTTCGACC                           
  Mit-2         F           CGATCAACCTCACCACCTCT      1226-2026            59.7
                R           TGGACAACCAGCTATCACCA                           
  Mit-3         F           GGACTAACCCCTATACCTTCTGC   1930-2688            58
                R           GGCAGGTCAATTTCACTGGT                           
  Mit-4         F           AAATCTTACCCCGCCTGTTT      2480-3365            58
                R           AGGAATGCCATTGCGATTAG                           
  Mit-5         F           TACTTCACAAAGCGCCTTCC      3150-3980            58
                R           ATGAAGAATAGGGCGAAGGG                           
  Mit-6         F           TGGCTCCTTTAACCTCTCCA      3777-4679            59
                R           AAGGATTATGGATGCGGTTG                           
  Mit-7         F           ACTAATTAATCCCCTGGCCC      4466-5443            59
                R           CCTGGGGTGGGTTTTGTATG                           
  Mit-8         F           CTAACCGGCTTTTTGCCC        5238-6050            56
                R           ACCTAGAAGGTTGCCTGGCT                           
  Mit-9         F           GAGGCCTAACCCCTGTCTTT      5835-6661            59
                R           ATTCCGAAGCCTGGTAGGAT                           
  Mit-10        F           CTCTTCGTCTGATCCGTCCT      6450-7334            59
                R           AGCGAAGGCTTCTCAAATCA                           
  Mit-11        F           ACGCCAAAATCCATTTCACT      7129-8114            59.7
                R           CGGGAATTGCATCTGTTTTT                           
  Mit-12        F           ACGAGTACACCGACTACGGC      7908-8816            59.7
                R           TGGGTGGTTGGTGTAAATGA                           
  Mit-13        F           TTTCCCCCTCTATTGATCCC      8602-9416            59
                R           GTGGCCTTGGTATGTGCTTT                           
  Mit-14        F           CCCACCAATCACATGCCTAT      9211-10149           58
                R           TGTAGCCGTTGAGTTGTGGT                           
  Mit-15        F           TCTCCATCTATTGATGAGGGTCT   9967-10858           58
                R           AATTAGGCTGTGGGTGGTTG                           
  Mit-16        F           GCCATACTAGTCTTTGCCGC      10653-11511          59
                R           TTGAGAATGAGTGTGAGGCG                           
  Mit-17        F           TCACTCTCACTGCCCAAGAA      11295-12095          59
                R           GGAGAATGGGGGATAGGTGT                           
  Mit-18        F           TATCACTCTCCTACTTACAG      11929-12793          54
                R           AGAAGGTTATAATTCCTACG                           
  Mit-19        F           AAACAACCCAGCTCTCCCTAA     12551-13526          59
                R           TCGATGATGTGGTCTTTGGA                           
  Mit-20        F           ACATCTGTACCCACGCCTTC      13319-14287          55
                R           AGAGGGGTCAGGGTTCATTC                           
  Mit-21        F           GCATAATTAAACTTTACTTC      14081-15017          55
                R           AGAATATTGAGGCGCCATTG                           
  Mit-22        F           TGAAACTTCGGCTCACTCCT      14837-15997          58
                R           AGCTTTGGGTGCTAATGGTG                           
  Mit-23        F           TCATTGGACAAGTAGCATCC      15792-31             59.7
                R           GAGTGGTTAATAGGGTGATAG                          
  Mit-24        F           CACCATTCTCCGTGAAATCA      16401-794            59.7
                R           AGGCTAAGCGTTTTGAGCTG                           

F, forward; R, reverse; Tm, Annealing Temperature.

###### 

Summary of the clinical data for probands in two Chinese families.

  Proband   Sex      Age at audiological test, year   Age at onset, year   Use of AmAn   PTA, dB Right ear   PTA, dB Left ear   Level of hearing loss
  --------- -------- -------------------------------- -------------------- ------------- ------------------- ------------------ -----------------------
  III-12    Female   15                               10                   No            118                 110                Profound
  II-9      Female   38                               20                   No            103                   99               Profound
  III-4     Female   10                               --                   No              21                  19               Normal

AmAn, aminoglycoside antibiotics.

###### 

MtDNA mutations in the two Chinese families with hearing loss.

  Gene                 Position    Mutation              Conservation (H/B/M/X)   rCRS   Family 1   Family 2   Previously reported^[a](#tfn3-mmr-22-01-0077){ref-type="table-fn"}^
  -------------------- ----------- --------------------- ------------------------ ------ ---------- ---------- ---------------------------------------------------------------------
  D-Loop               73          A to G                                         A      G                     Yes
                       150         C to T                                         C                            Yes
                       263         A to G                                         A                 G          Yes
                       310         T to CTC                                       T      CTC        CTC        Yes
                       489         T to C                                         T                 C          Yes
                       16093       T to C                                         T                 C          Yes
                       16111       C to T                                         C      T                     Yes
                       16189       T to C                                         T      C                     Yes
                       16362       T to C                                         T                 C          Yes
                       16519       T to C                                         T      C          C          Yes
  12S rRNA             750         A to G                A/A/G/-                  A      G          G          Yes
                       827         A to G                                         A                 G          Yes
                       1048        C to T                                         C      T                     Yes
                       1438        A to G                A/A/A/G                  A      G          G          Yes
  16S rRNA             2706        A to G                A/G/A/A                  A      G          G          Yes
                       3010        G to A                G/G/A/A                  G      A                     Yes
                       3107        delN                                           N                 delN       Yes
                       3206        C to T                                         C      T                     Yes
  ND1                  3759        A to G                                         A                 G          Yes
                       3771        A to G                                         A      G                     Yes
                       3970        C to T                                         C      T          T          Yes
  ND2                  4685        A to G                                         A                 G          Yes
                       4769        A to G                                         A      G                     Yes
                       4883        C to T                                         C                 T          Yes
  CO1                  6284        A to G                                         A      G                     Yes
                       7028        C to T                                         C                 T          Yes
                       7066        C to T                                         C      T                     Yes
  CO1/tRNA^Ser(UCN)^   7444        G to A (Ser to Lys)   G/G/G/G                  G      A                     Yes
  tRNA^Ser(UCN)^       7492        C to T                C/C/C/C                  C                 T          Yes
  CO~2~                7976        G to A                                         G                 A          Yes
                       8080        C to G                                         C                 G          Yes
  NC7                  8271-8279   9-bp del              T/S/L/Q                  9-bp              9-bp del   Yes
  ATP6                 8701        A to G (Thr to Ala)   M/M/M/F                  A      G          G          Yes
                       8725        A to G                                         A      G                     Yes
                       8860        A to G (Thr to Ala)   T/A/A/T                  A      G          G          Yes
                       9128        T to C                                         T                 C          Yes
  CO3                  9540        T to C                                         T      C                     Yes
  ND3                  10398       A to G (Thr to Ala)   T/T/T/A                  A      G                     Yes
  ND4L                 10493       T to C                                         T                 C          Yes
  ND4                  10873       T to C                                         T      C                     Yes
                       11440       G to A                                         G                 A          Yes
  ND5                  12705       C to T                                         C      T                     Yes
  ND6                  14455       C to T                                         C      T                     Yes
  CytB                 14766       C to T (Thr to Ile)   T/S/T/S                  C                 T          Yes
                       15301       G to A                                         G      A          A          Yes
                       15326       A to G (Thr to Ala)   T/M/I/I                  A      G          G          Yes
                       15784       T to C                                         T      C          C          Yes

Human MITOMAP database ([www.mitomap.org](www.mitomap.org)). H, human; B, bovine; M, mouse; X, *Xenopus laevis*; rCRS, revised Cambridge Reference Sequences; ND, NADH-ubiquinone oxidoreductase chain; CO, cytochrome *c* oxidase; CytB, Cytochrome B; ATP6, ATP synthase membrane subunit 6; tRNA, transfer RNA; Lys, lysine; Thr, threonine; Ala, alanine; Ile, isoleucine; del, deletion.

###### 

Pathogenicity scoring system for G7444A and C7492T mutations.

  Scoring criteria                                                                                       G7444A mutation       Score/20   C7492T mutation       Score/20
  ------------------------------------------------------------------------------------------------------ --------------------- ---------- --------------------- ----------
  \>1 independent report                                                                                 Yes                   2          Yes                   2
  Evolutionary conservation of the base pair                                                             No changes            2          No changes            2
  Variant heteroplasmy                                                                                   No                    0          No                    0
  Segregation of the mutation with disease                                                               Yes                   2          Yes                   2
  Histochemical evidence of mitochondrial disease                                                        No evidence           0          No evidence           0
  Biochemical defect in complex I, III or IV                                                             No                    0          No                    0
  Evidence of mutation segregation with biochemical defect from single-fiber studies                     No                    0          No                    0
  Mutant mt-tRNA steady-state level or evidence of pathogenicity in trans-mitochondrial cybrid studies   Weak evidence         3          Weak evidence         3
  Maximum score                                                                                          Possibly pathogenic   9          Possibly pathogenic   9

Classification: ≤6 points: 'neutral polymorphisms'; 7--10 points: 'possibly pathogenic'; 11--13 points (not including evidence from single fiber, steady-state level or trans-mitochondrial cybrid studies): 'probably pathogenic'; ≥11 points (including evidence from single fiber, steady-state level or trans-mitochondrial cybrid studies): 'definitely pathogenic'. mt-tRNA, mitochondrial DNA-transfer RNA.
